Response of basal cell carcinoma to imiquimod was associated with the Gli1 : Gli3 expression ratio

Br J Dermatol. 2018 Dec;179(6):1406-1407. doi: 10.1111/bjd.17015. Epub 2018 Oct 14.

Authors

A Kanzaki^{1

2}, Y Kato^{1

3}, T Kariya^{1

2}, Y Kanda^{1

2}, K Shirai^{1

2}, T Arai^{1

2}, R Tsuboi²

Affiliations

¹ Department of Dermatology, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan.
² Department of Dermatology, Tokyo Medical University, Tokyo, Japan.
³ Department of Dermatology, Tokyo Medical University Hachioji Medical Center, 1163 Tatemachi, Hachioji, Tokyo, 193-0944, Japan.

PMID: 30019418
DOI: 10.1111/bjd.17015

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Administration, Cutaneous
Aged, 80 and over
Biomarkers, Tumor / metabolism
Biopsy
Carcinoma, Basal Cell / drug therapy*
Carcinoma, Basal Cell / pathology
Female
Humans
Imiquimod / administration & dosage*
Male
Middle Aged
Nerve Tissue Proteins / metabolism*
Skin / drug effects
Skin / pathology
Skin Cream / administration & dosage
Skin Neoplasms / drug therapy*
Skin Neoplasms / pathology
Treatment Outcome
Zinc Finger Protein GLI1 / metabolism*
Zinc Finger Protein Gli3 / metabolism*

Substances

Biomarkers, Tumor
GLI1 protein, human
GLI3 protein, human
Nerve Tissue Proteins
Zinc Finger Protein GLI1
Zinc Finger Protein Gli3
Imiquimod